Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma

Figure 9

Evaluation and validation of the prognostic signature. (a) AUC of time-dependent ROC curves in TCGA at 1 year, 2 years, and 3 years. (b) K-M analysis of the risk score in TCGA. (c, d) Forest plot of the univariate and multivariate regression analysis in TCGA cohort. (e) Nomogram based on the risk score and other clinical features for predicting 1- to 3-year OS in TCGA. (f) Calibration graphs investigated that whether the nomogram predicted survival rates were close to the actual survival rates. (g) ROC analysis of the nomogram model in TCGA (h) AUC of time-dependent ROC curves in ICGC at 1 year, 2 years, and 3 years. (i) K-M analysis of the risk score in the ICGC cohort. (j) ROC analysis of the nomogram model in ICGC. (k) AUC of time-dependent ROC curves in GSE14520 at 1 year, 2 years, and 3 years. (l) K-M analysis of the risk score in the GSE14520 cohort. (m) ROC analysis of the nomogram model in GSE14520.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)